Gertjan J L Kaspers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1300893/publications.pdf

Version: 2024-02-01

519 papers

20,348 citations

70 h-index 119 g-index

529 all docs

529 docs citations

529 times ranked 21776 citing authors

#	Article	IF	CITATIONS
1	SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resourceâ€limited settings. Pediatric Blood and Cancer, 2023, 70, e28087.	1.5	21
2	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Pediatric Blood and Cancer, 2022, 69, e29341.	1. 5	5
3	Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. Cancer Reports, 2022, 5, e1576.	1.4	4
4	Health-care providers' perception and communication about traditional and complementary medicine in childhood cancer in Indonesia. Pediatric Hematology Oncology Journal, 2022, 7, 4-9.	0.1	3
5	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 612.	3.7	10
6	Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHOâ€ÐB SHIP consortium. British Journal of Haematology, 2022, , .	2.5	5
7	Prevalence of Sleep Disorders, Risk Factors and Sleep Treatment Needs of Adolescents and Young Adult Childhood Cancer Patients in Follow-Up after Treatment. Cancers, 2022, 14, 926.	3.7	3
8	20 years of Expert Review of Anticancer Therapy. Expert Review of Anticancer Therapy, 2022, 22, 1-2.	2.4	2
9	Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch populationâ€based study. International Journal of Cancer, 2022, 150, 1101-1112.	5.1	5
10	Outcomes of Wilms tumor treatment in western Kenya. Pediatric Blood and Cancer, 2022, 69, e29503.	1.5	5
11	Impact of COVIDâ€19 measures on a paediatric oncology outreachâ€program. Psycho-Oncology, 2022, 31, 860-864.	2.3	6
12	Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma. Translational Medicine Communications, 2022, 7, .	1.4	8
13	AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma. IScience, 2022, 25, 104398.	4.1	10
14	An evaluation of the disparities affecting the underdiagnosis of pediatric cancer in Western Kenya. Pediatric Blood and Cancer, 2022, 69, e29768.	1.5	3
15	Parental Sleep, Distress, and Quality of Life in Childhood Acute Lymphoblastic Leukemia: A Longitudinal Report from Diagnosis up to Three Years Later. Cancers, 2022, 14, 2779.	3.7	5
16	Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study. Cancers, 2022, 14, 2754.	3.7	0
17	Effect of Antibacterial Prophylaxis on Febrile Neutropenic Episodes and Bacterial Bloodstream Infections in Dutch Pediatric Patients with Acute Myeloid Leukemia: A Two-Center Retrospective Study. Cancers, 2022, 14, 3172.	3.7	1
18	Insomnia Symptoms and Daytime Fatigue Co-Occurrence in Adolescent and Young Adult Childhood Cancer Patients in Follow-Up after Treatment: Prevalence and Associated Risk Factors. Cancers, 2022, 14, 3316.	3.7	3

#	Article	IF	Citations
19	Psychometric properties of the Patientâ€Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance and Sleepâ€Related Impairment item banks in adolescents. Journal of Sleep Research, 2021, 30, e13029.	3.2	12
20	A meta-analysis of accelerometer sleep outcomes in healthy children based on the Sadeh algorithm: the influence of child and device characteristics. Sleep, 2021, 44, .	1.1	7
21	Pediatric relapsed acute myeloid leukemia: a systematic review. Expert Review of Anticancer Therapy, 2021, 21, 45-52.	2.4	23
22	Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. Leukemia, 2021, 35, 2403-2406.	7.2	8
23	Parental sleep after induction therapy for childhood acute lymphoblastic leukemia. Journal of Psychosocial Oncology Research and Practice, 2021, 3, e045.	0.5	3
24	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. Ecancermedicalscience, 2021, 15, 1187.	1.1	4
25	Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. Cells, 2021, 10, 665.	4.1	8
26	Measurable residual disease in pediatric acute myeloid leukemia: a systematic review. Expert Review of Anticancer Therapy, 2021, 21, 451-459.	2.4	7
27	Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Review of Anticancer Therapy, 2021, 21, 765-780.	2.4	10
28	Does the guided online cognitive behavioral therapy for insomnia "i-Sleep youth―improve sleep of adolescents and young adults with insomnia after childhood cancer? (MICADO-study): study protocol of a randomized controlled trial. Trials, 2021, 22, 307.	1.6	5
29	Radiosensitization in Pediatric High-Grade Glioma: Targets, Resistance and Developments. Frontiers in Oncology, 2021, 11, 662209.	2.8	13
30	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 2021, 13, 2336.	3.7	30
31	Complementary and alternative medicine in children with diffuse intrinsic pontine glioma—A SIOPE DIPG Network and Registry study. Pediatric Blood and Cancer, 2021, 68, e29061.	1.5	4
32	A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2021, 153, 263-271.	2.9	15
33	SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia. Leukemia, 2021, 35, 2698-2702.	7.2	9
34	Treatment Outcome of Children with Retinoblastoma in a Tertiary Care Referral Hospital in Indonesia. Asian Pacific Journal of Cancer Prevention, 2021, 22, 1613-1621.	1.2	4
35	Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. British Journal of Haematology, 2021, 194, 423-432.	2.5	3
36	How I treat pediatric acute myeloid leukemia. Blood, 2021, 138, 1009-1018.	1.4	40

#	Article	IF	CITATIONS
37	Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2025-2031.	1.2	3
38	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. Cancers, 2021, 13, 4364.	3.7	5
39	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 2021, 13, 4598.	3.7	8
40	Childhood acute lymphoblastic leukemia treatment in an academic hospital in Kenya: Treatment outcomes and healthâ€care providers' perspectives. Pediatric Blood and Cancer, 2021, 68, e29366.	1.5	4
41	Female reproductive function after treatment of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28894.	1.5	5
42	The association between vincristineâ€induced peripheral neuropathy and healthâ€related quality of life in children with cancer. Cancer Medicine, 2021, 10, 8172-8181.	2.8	13
43	Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells. Blood, 2021, 138, 2227-2227.	1.4	0
44	Increased Survival Disparities Among Children and Adolescents & Young Adults with Acute Myeloid Leukemia: A Dutch Population-Based Study. Blood, 2021, 138, 845-845.	1.4	0
45	Influence of health insurance status on childhood cancer treatment outcomes in Kenya. Supportive Care in Cancer, 2020, 28, 917-924.	2.2	12
46	Communication about Traditional Complementary and Alternative Medicine (TCAM) in childhood cancer: A comparison between Dutch and Indonesian health-care providers at academic hospitals. Advances in Integrative Medicine, 2020, 7, 89-95.	0.9	2
47	Development of an evidence-based decision aid on complementary and alternative medicine (CAM) and pain for parents of children with cancer. Supportive Care in Cancer, 2020, 28, 2415-2429.	2.2	13
48	MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 58-69.	1.2	21
49	Measuring vincristine-induced peripheral neuropathy in children with cancer: validation of the Dutch pediatric–modified Total Neuropathy Score. Supportive Care in Cancer, 2020, 28, 2867-2873.	2.2	14
50	TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia. British Journal of Haematology, 2020, 188, 736-739.	2.5	6
51	Sleep–wake rhythm disruption is associated with cancer-related fatigue in pediatric acute lymphoblastic leukemia. Sleep, 2020, 43, .	1.1	25
52	Causes of early death and treatmentâ€related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group. Pediatric Blood and Cancer, 2020, 67, e28099.	1.5	17
53	Determinants of health-related quality of life proxy rating disagreement between caregivers of children with cancer. Quality of Life Research, 2020, 29, 901-912.	3.1	23
54	Parental functioning during maintenance treatment for childhood acute lymphoblastic leukemia: Effects of treatment intensity and dexamethasone pulses. Pediatric Blood and Cancer, 2020, 67, e28697.	1.5	10

#	Article	IF	Citations
55	The role of alternative splicing in cancer: From oncogenesis to drug resistance. Drug Resistance Updates, 2020, 53, 100728.	14.4	118
56	Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 1346-1346.	1.1	2
57	Working Together to Build a Better Future for Children With Cancer in Africa. JCO Global Oncology, 2020, 6, 1076-1078.	1.8	13
58	Overview of Current Drug Delivery Methods Across the Blood–Brain Barrier for the Treatment of Primary Brain Tumors. CNS Drugs, 2020, 34, 1121-1131.	5 . 9	73
59	Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). Cancers, 2020, 12, 3745.	3.7	12
60	Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia. Cancers, 2020, 12, 1247.	3.7	8
61	COVID-19: how will this impact children with cancer, now and in the future?. Expert Review of Anticancer Therapy, 2020, 20, 527-529.	2.4	16
62	Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2020, 26, 3319-3332.	7.0	44
63	Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation. Cancers, 2020, 12, 723.	3.7	16
64	Actigraphic estimates of sleep and the sleep-wake rhythm, and 6-sulfatoxymelatonin levels in healthy Dutch children. Chronobiology International, 2020, 37, 660-672.	2.0	13
65	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	3.7	18
66	High prevalence of parentâ€reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy. Pediatric Blood and Cancer, 2020, 67, e28165.	1.5	23
67	Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 1379-1388.	1.1	6
68	The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia. Supportive Care in Cancer, 2020, 28, 5983-5993.	2.2	17
69	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27.	1.4	1
70	Health insurance coverage for vulnerable children: two HIV orphans with Burkitt lymphoma and their quest for health insurance coverage in Kenya. BMJ Case Reports, 2020, 13, e230508.	0.5	1
71	Global Problem of Hospital Detention Practices. International Journal of Health Policy and Management, 2020, 9, 319-326.	0.9	1
72	A High-Throughput Image-Guided Stereotactic Neuronavigation and Focused Ultrasound System for Blood-Brain Barrier Opening in Rodents. Journal of Visualized Experiments, 2020, , .	0.3	1

#	Article	IF	CITATIONS
7 3	PATH-04. THE BLOOD-BRAIN BARRIER IN DIFFUSE MIDLINE GLIOMA AND ITS IMPLICATIONS FOR DRUG DELIVERY. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
74	Longitudinal development of cancerâ€related fatigue and physical activity in childhood cancer patients. Pediatric Blood and Cancer, 2019, 66, e27949.	1.5	58
7 5	Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. Cancer Medicine, 2019, 8, 6634-6643.	2.8	8
76	Responseâ€guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AMLâ€01. Pediatric Blood and Cancer, 2019, 66, e27605.	1.5	26
77	Concurrence of sleep problems and distress: prevalence and determinants in parents of children with cancer. Högre Utbildning, 2019, 10, 1639312.	3.0	16
78	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
79	Uterine function, pregnancy complications, and pregnancy outcomes among female childhood cancer survivors. Fertility and Sterility, 2019, 111, 372-380.	1.0	56
80	Preclinical therapeutic targets in diffuse midline glioma. Drug Resistance Updates, 2019, 44, 15-25.	14.4	19
81	Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. Leukemia Research, 2019, 81, 27-34.	0.8	11
82	Acute myeloid leukaemia niche regulates response to Lâ€asparaginase. British Journal of Haematology, 2019, 186, 397-399.	2.5	10
83	Use of granulocyte colonyâ€stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHOâ€AML 2004 and DB AMLâ€01. Pediatric Blood and Cancer, 2019, 66, e27701.	1.5	10
84	Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. Leukemia Research, 2019, 79, 45-51.	0.8	17
85	Genderâ€specific differences in parental healthâ€related quality of life in childhood cancer. Pediatric Blood and Cancer, 2019, 66, e27728.	1.5	26
86	Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin. EBioMedicine, 2019, 50, 81-92.	6.1	23
87	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine, 2019, 39, 215-225.	6.1	41
88	Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia, 2019, 33, 1349-1359.	7.2	39
89	A costâ€effectiveness analysis of <i>Erwinia</i> asparaginase therapy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27458.	1.5	14
90	All It Takes for Corruption in Health Systems to Triumph, Is Good People Who Do Nothing Comment on "We Need to Talk About Corruption in Health Systems". International Journal of Health Policy and Management, 2019, 8, 610-612.	0.9	2

#	Article	IF	Citations
91	An effective modestly intensive reâ€induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 181, 523-527.	2.5	12
92	RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. Blood, 2018, 131, 2485-2489.	1.4	22
93	Reproductive intentions and use of reproductive health care among female survivors of childhood cancer. Human Reproduction, 2018, 33, 1167-1174.	0.9	25
94	Improved outcome at end of treatment in the collaborative Wilms tumour Africa project. Pediatric Blood and Cancer, 2018, 65, e26945.	1.5	27
95	Clinical challenges in <i>de novo</i> pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 2018, 18, 277-293.	2.4	28
96	3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients. European Journal of Cancer, 2018, 90, 102-110.	2.8	15
97	Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group. Pediatric Blood and Cancer, 2018, 65, e27083.	1.5	18
98	Validation of the PROMIS Sleep Disturbance and Sleep-Related Impairment item banks in Dutch adolescents. Quality of Life Research, 2018, 27, 1911-1920.	3.1	18
99	Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. Journal of Visualized Experiments, 2018, , .	0.3	23
100	Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. British Journal of Haematology, 2018, 183, 512-516.	2.5	27
101	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2018, 59, 612-615.	5.0	24
102	Signaling pathways and mesenchymal transition in pediatric high-grade glioma. Cellular and Molecular Life Sciences, 2018, 75, 871-887.	5 . 4	44
103	<i>CYP3A5</i> genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatric Blood and Cancer, 2018, 65, e26854.	1.5	37
104	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. Journal of Clinical Oncology, 2018, 36, 1963-1972.	1.6	250
105	ATRT-19. PRECLINICAL EFFICACY OF COMBINED INHIBITION OF MEK AND MELK IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2018, 20, i31-i31.	1.2	0
106	Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A <scp>NOPHO</scp> â€ <scp>DBH</scp> â€ <scp>AML</scp> study. British Journal of Haematology, 2018, 183, 618-628.	2.5	8
107	Effects of a combined physical and psychosocial training for children with cancer: a randomized controlled trial. BMC Cancer, 2018, 18, 1289.	2.6	37
108	DIPG-05. PRECLINICAL EFFICACY OF MELK INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2018, 20, i49-i50.	1.2	0

#	Article	IF	CITATIONS
109	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica, 2018, 103, 1484-1492.	3.5	24
110	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood, 2018, 132, 405-412.	1.4	46
111	Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2018, 65, e27231.	1.5	8
112	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2018, 24, 5645-5657.	7.0	30
113	Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin–Frankfürt–Münster (lâ€ <scp>BFM</scp>) study group. British Journal of Haematology, 2018, 183, 87-95.	2.5	8
114	Healthâ€care providers' perspectives on traditional and complementary alternative medicine of childhood cancer in Kenya. Pediatric Blood and Cancer, 2018, 65, e27309.	1.5	13
115	An efficient method for the transduction of primary pediatric glioma neurospheres. MethodsX, 2018, 5, 173-183.	1.6	12
116	Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Human Reproduction, 2018, 33, 1474-1488.	0.9	48
117	Health are providers' perspectives on healthâ€insurance access, waiving procedures, and hospital detention practices in Kenya. Pediatric Blood and Cancer, 2018, 65, e27221.	1.5	7
118	Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma. Blood, 2018, 132, 5200-5200.	1.4	0
119	Cumulative Incidence of Blood Stream Infections during Acute Myeloid Leukemia Treatment in the Netherlands: A 15-Year Overview. Blood, 2018, 132, 2685-2685.	1.4	0
120	Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. The Cochrane Library, 2017, 2017, CD008796.	2.8	151
121	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
122	Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients. European Journal of Cancer, 2017, 72, 235-243.	2.8	57
123	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica, 2017, 102, 552-561.	3.5	14
124	Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2017, 114, 114-130.	4.4	124
125	External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. Journal of Neuro-Oncology, 2017, 134, 231-240.	2.9	21
126	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatric Blood and Cancer, 2017, 64, e26664.	1.5	14

#	Article	IF	Citations
127	Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Annals of Hematology, 2017, 96, 1449-1456.	1.8	32
128	Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AMLâ€M4). Pediatric Blood and Cancer, 2017, 64, e26512.	1.5	3
129	Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Journal of Neurosurgery: Pediatrics, 2017, 19, 518-530.	1.3	23
130	Psychometric properties and Dutch norm values of the Children's Sleep Habits Questionnaire in toddlers. Sleep Medicine, 2017, 34, 57-63.	1.6	12
131	An 8-Year-Old Girl with Ocular Swelling. Journal of Pediatrics, 2017, 181, 324-324.e1.	1.8	0
132	Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. Experimental Cell Research, 2017, 360, 397-403.	2.6	26
133	A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 2017, 135, 307-315.	2.9	25
134	A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26651.	1.5	16
135	(Immuno)proteasomes as therapeutic target in acute leukemia. Cancer and Metastasis Reviews, 2017, 36, 599-615.	5.9	29
136	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. The Cochrane Library, 2017, 2017, CD008727.	2.8	41
137	Cost-effectiveness of a combined physical exercise and psychosocial training intervention for children with cancer: Results from the quality of life in motion study. European Journal of Cancer Care, 2017, 26, e12586.	1.5	11
138	Genomic landscape of retinoblastoma in $\langle i\rangle$ Rb $\langle sup\rangle$ â 2 lâ 2 $\langle sup\rangle$ p130 $\langle sup\rangle$ â 2 lâ 2 $\langle sup\rangle$ li \rangle mice resembles human retinoblastoma. Genes Chromosomes and Cancer, 2017, 56, 231-242.	2.8	5
139	Strategies for reducing the treatmentâ€related physical burden of childhood acute myeloid leukaemia – a review. British Journal of Haematology, 2017, 176, 168-178.	2.5	15
140	Molecular Drug Imaging: ⁸⁹ Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. Journal of Nuclear Medicine, 2017, 58, 711-716.	5.0	69
141	Real-world implementation of electronic patient-reported outcomes in outpatient pediatric cancer care. Psycho-Oncology, 2017, 26, 951-959.	2.3	61
142	Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer Treatment Reviews, 2017, 53, 10-24.	7.7	101
143	Influence of health insurance status on paediatric non-Hodgkin's lymphoma treatment in Kenya. BMJ Paediatrics Open, 2017, 1, e000149.	1.4	18
144	Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. Frontiers in Oncology, 2017, 7, 254.	2.8	25

#	Article	IF	Citations
145	DIPG-15. EFFECTIVE PRECLINICAL TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA BY MELK INHIBITION. Neuro-Oncology, 2017, 19, iv7-iv8.	1.2	0
146	Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma. Oncotarget, 2017, 8, 78978-78988.	1.8	4
147	Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting. Journal of Global Oncology, 2017, 3, 555-562.	0.5	29
148	Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. Oncotarget, 2017, 8, 60447-60452.	1.8	20
149	A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression. PLoS ONE, 2016, 11, e0153323.	2.5	55
150	A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. Oncotarget, 2016, 7, 35776-35788.	1.8	17
151	mi <scp>R</scp> expression profiling at diagnosis predicts relapse in pediatric precursor <scp>B</scp> â€eell acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2016, 55, 328-339.	2.8	32
152	Content validity of the Patient-Reported Outcomes Measurement Information System Sleep Disturbance and Sleep Related Impairment item banks in adolescents. Health and Quality of Life Outcomes, 2016, 14, 92.	2.4	16
153	Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. Scientific Reports, 2016, 6, 25264.	3.3	75
154	The prevalence and risk factors of sleep problems in pediatric oncology: its effect on quality of life during and after cancer treatment. Expert Review of Quality of Life in Cancer Care, 2016, 1, 153-171.	0.6	15
155	State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. Journal of Neuro-Oncology, 2016, 128, 387-394.	2.9	18
156	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Journal of Hematology and Oncology, 2016, 9, 82.	17.0	22
157	Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. British Journal of Haematology, 2016, 175, 588-601.	2.5	14
158	Comparing Healthâ€Care Providers' Perspectives on Complementary and Alternative Medicine in Childhood Cancer Between Netherlands and Indonesia. Pediatric Blood and Cancer, 2016, 63, 118-123.	1.5	6
159	Delays in diagnosis and treatment of childhood cancer in Indonesia. Pediatric Blood and Cancer, 2016, 63, 2189-2196.	1.5	32
160	Factors influencing time to diagnosis and treatment among pediatric oncology patients in Kenya. Pediatric Hematology and Oncology, 2016, 33, 186-199.	0.8	37
161	The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia. Haematologica, 2016, 101, e291-e294.	3.5	17
162	Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts. Pediatric Blood and Cancer, 2016, 63, 1457-1460.	1.5	14

#	Article	IF	CITATIONS
163	Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial. Psycho-Oncology, 2016, 25, 815-822.	2.3	42
164	Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. International Journal of Cancer, 2016, 138, 1645-1656.	5.1	33
165	Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. Journal of Clinical Oncology, 2016, 34, 2591-2601.	1.6	287
166	Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models. Molecular Cancer Therapeutics, 2016, 15, 2166-2174.	4.1	51
167	Combining Clofarabine and Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia: An Effective, Low Toxicity TBI-Free Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2016, 22, S99-S100.	2.0	2
168	Screening for Psychosocial Risk in Dutch Families of a Child With Cancer: Reliability, Validity, and Usability of the Psychosocial Assessment Tool. Journal of Pediatric Psychology, 2016, 41, 810-819.	2.1	20
169	Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in <scp><i>ZMYND11/MBTD1</i></scp> fusion. Genes Chromosomes and Cancer, 2016, 55, 237-241.	2.8	22
170	<scp>CD</scp> 45 <scp>RA</scp> , a specific marker for leukaemia stem cell subâ€populations in acute myeloid leukaemia. British Journal of Haematology, 2016, 173, 219-235.	2.5	47
171	Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis. Molecular and Cellular Proteomics, 2016, 15, 1281-1298.	3.8	90
172	Cardiorespiratory fitness and physical activity in children with cancer. Supportive Care in Cancer, 2016, 24, 2259-2268.	2.2	58
173	Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 2016, 16, 137-146.	2.4	17
174	Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia, 2016, 30, 1599-1603.	7.2	50
175	Palliative and end-of-life care for children with diffuse intrinsic pontine glioma: results from a London cohort study and international survey. Neuro-Oncology, 2016, 18, 582-588.	1.2	25
176	The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study. Blood, 2016, 128, 2896-2896.	1.4	1
177	MicroRNA-106b~25 cluster is upregulated in relapsed <i>MLL</i> rearranged pediatric acute myeloid leukemia. Oncotarget, 2016, 7, 48412-48422.	1.8	20
178	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Oncotarget, 2016, 7, 74779-74796.	1.8	16
179	Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models. Journal of Visualized Experiments, 2016, , .	0.3	16
180	Parental Experiences with Chemotherapy-Induced Alopecia among Childhood Cancer Patients in Indonesia. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1717-1723.	1.2	5

#	Article	IF	Citations
181	Abstract 4336: Spliceosome inhibition as a novel therapeutic option in acute leukemia., 2016,,.		O
182	Abstract 332: Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma. , $2016, , .$		0
183	Executive Dysfunction 25 Years after Treatment with Cranial Radiotherapy for Pediatric Lymphoid Malignancies. Journal of the International Neuropsychological Society, 2015, 21, 657-669.	1.8	15
184	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. The Cochrane Library, 2015, , CD008727.	2.8	8
185	Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2015, 8, 61.	17.0	49
186	No Efficacy for Silicone Gel Sheeting in Prevention of Abnormal Scar Formation in Children with Cancer. Plastic and Reconstructive Surgery, 2015, 135, 1086-1094.	1.4	9
187	EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System. Molecular Cancer Research, 2015, 13, 982-992.	3.4	19
188	Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Mýnster Study Group. Journal of Clinical Oncology, 2015, 33, 4247-4258.	1.6	75
189	Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 673-689.	3.3	45
190	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resistance Updates, 2015, 18, 18-35.	14.4	153
191	MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 222-230.	6.4	16
192	Parental experiences of childhood cancer treatment in Kenya. Supportive Care in Cancer, 2015, 23, 1251-1259.	2.2	36
193	Corruption in health-care systems and its effect on cancer care in Africa. Lancet Oncology, The, 2015, 16, e394-e404.	10.7	54
194	Factors influencing childhood cancer patients to participate in a combined physical and psychosocial intervention program: Quality of Life in Motion. Psycho-Oncology, 2015, 24, 465-471.	2.3	18
195	Applicability and evaluation of a psychosocial intervention program for childhood cancer patients. Supportive Care in Cancer, 2015, 23, 2327-2333.	2.2	13
196	A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Review of Anticancer Therapy, 2015, 15, 157-164.	2.4	41
197	Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression. EBioMedicine, 2015, 2, 660-670.	6.1	54
198	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	1.6	277

#	Article	IF	CITATIONS
199	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro-Oncology, 2015, 17, 160-166.	1.2	124
200	Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics. Blood, 2015, 126, 2501-2501.	1.4	1
201	Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01. Blood, 2015, 126, 2506-2506.	1.4	5
202	The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia. Blood, 2015, 126, 2584-2584.	1.4	1
203	Risk-Group Stratified and Minimal Residual Disease (MRD)-Guided Treatment with Extended ATRA and Reduced-Anthracycline Chemotherapy in Childhood Acute Promyelocytic Leukemia (APL): Results from ICC APL Study 01 (NCT01226303; EudraCT 2008-002311-40). Blood, 2015, 126, 563-563.	1.4	2
204	Gene Expression Profiles Associated with Pediatric Relapsed AML. PLoS ONE, 2015, 10, e0121730.	2.5	22
205	Abstract 1624: Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia., 2015,,.		0
206	Abstract 4437: The relevance of aberrant FPGS splicing for ex vivo MTX resistance and clinical outcome in childhood acute lymphoblastic leukemia. Cancer Research, 2015, 75, 4437-4437.	0.9	2
207	Glucocorticoid-Induced Proliferation and Lack of Differentation in Untreated Pediatric Acute Myeloid Leukemic Blasts. Blood, 2015, 126, 4843-4843.	1.4	0
208	Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients. Blood, 2015, 126, 1281-1281.	1.4	2
209	Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study. Blood, 2015, 126, 172-172.	1.4	1
210	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712.	1.4	0
211	Abstract B27: Toxicity of convection-enhanced delivery with doxorubicin to treat pediatric brain-tumors depends on anatomical location. , 2015 , , .		0
212	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica, 2014, 99, 1472-1478.	3.5	42
213	Management of Children with Wilms Tumor in Africa and Europe; Thoughts About Costs, Priorities and Collaboration. Pediatric Hematology and Oncology, 2014, 31, 395-399.	0.8	3
214	Health Status Utilities in Pediatrics. Medical Decision Making, 2014, 34, 21-32.	2.4	18
215	Abandonment of childhood cancer treatment in Western Kenya. Archives of Disease in Childhood, 2014, 99, 609-614.	1.9	69
216	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica, 2014, 99, 865-872.	3.5	77

#	Article	IF	Citations
217	Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but not Long-term Survival. Klinische Padiatrie, 2014, 226, 323-331.	0.6	3
218	Two overlooked contributors to abandonment of childhood cancer treatment in Kenya: parents' social network and experiences with hospital retention policies. Psycho-Oncology, 2014, 23, 700-707.	2.3	50
219	Influence of healthâ€insurance access and hospital retention policies on childhood cancer treatment in Kenya. Pediatric Blood and Cancer, 2014, 61, 913-918.	1.5	36
220	Diversity in renal function monitoring and dose modifications during treatment for childhood cancer: A call for standardization. Pediatric Blood and Cancer, 2014, 61, 337-344.	1.5	4
221	Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. British Journal of Haematology, 2014, 166, 902-910.	2.5	22
222	Wilms tumour in Malawi: Surgical staging to stratify postoperative chemotherapy?. Pediatric Blood and Cancer, 2014, 61, 2180-2184.	1.5	3
223	Patient reported outcomes in pediatric oncology practice: Suggestions for future usage by parents and pediatric oncologists. Pediatric Blood and Cancer, 2014, 61, 1707-1710.	1.5	15
224	Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia. Supportive Care in Cancer, 2014, 22, 3235-3242.	2.2	18
225	Childhood Lymphomatoid Granulomatosis. Journal of Pediatric Hematology/Oncology, 2014, 36, e416-e422.	0.6	20
226	Why Pediatricians Fail to Diagnose Hypertension: A Multicenter Survey. Journal of Pediatrics, 2014, 164, 173-177.e7.	1.8	52
227	Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?. Supportive Care in Cancer, 2014, 22, 3-6.	2.2	24
228	18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma. EJNMMI Research, 2014, 4, 8.	2.5	4
229	Interferon- \hat{I}^3 -induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. Journal of Hematology and Oncology, 2014, 7, 7.	17.0	61
230	High resolution SNP array profiling identifies variability in retinoblastoma genome stability. Genes Chromosomes and Cancer, 2014, 53, 1-14.	2.8	25
231	Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration. Neuro-Oncology, 2014, 16, 946-959.	1.2	31
232	Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 422-433.	1.1	10
233	Het voorspellen van de gevoeligheid van kinderleukemiecellen voor proteasoomremmers. Tijdschrift Voor Kindergeneeskunde, 2014, 82, 79-88.	0.0	0
234	Unique BHLHB3 overexpression in pediatric acute myeloid leukemia with $t(6;11)(q27;q23)$. Leukemia, 2014, 28, 1564-1568.	7.2	3

#	Article	IF	CITATIONS
235	How I treat paediatric relapsed acute myeloid leukaemia. British Journal of Haematology, 2014, 166, 636-645.	2.5	27
236	Fertility studies in female childhood cancer survivors: selecting appropriate comparison groups. Reproductive BioMedicine Online, 2014, 29, 352-361.	2.4	10
237	Antileukemic Activity and Mechanism of Drug Resistance to the Marine <i>Salinispora tropica</i> Proteasome Inhibitor Salinosporamide A (Marizomib). Molecular Pharmacology, 2014, 86, 12-19.	2.3	39
238	Relevance of leukemic stem cells in acute myeloid leukemia: heterogeneity and influence on disease monitoring, prognosis and treatment design. Expert Review of Hematology, 2014, 7, 791-805.	2.2	13
239	Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1). Cancer Chemotherapy and Pharmacology, 2014, 73, 911-7.	2.3	4
240	Human pontine glioma cells can induce murine tumors. Acta Neuropathologica, 2014, 127, 897-909.	7.7	63
241	Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathologica, 2014, 128, 605-607.	7.7	74
242	Convection enhanced delivery of carmustine to the murine brainstem: A feasibility study. Journal of Neuroscience Methods, 2014, 238, 88-94.	2.5	22
243	Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. Biochemical Pharmacology, 2014, 89, 43-51.	4.4	36
244	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood, 2014, 123, 2026-2033.	1.4	177
245	Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and Bcll. Haematologica, 2014, 99, e136-e137.	3.5	11
246	ME-04 * SUBVENTRICULAR SPREAD OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2014, 16, v120-v120.	1.2	0
247	Adrenocortical carcinoma in children: First population-based clinicopathological study with long-term follow-up. Oncology Reports, 2014, 32, 2836-2844.	2.6	37
248	Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. Scientific Reports, 2014, 4, 5260.	3.3	35
249	Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ. Blood, 2014, 124, 2290-2290.	1.4	1
250	Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML. Blood, 2014, 124, 924-924.	1.4	7
251	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. Blood, 2014, 124, 989-989.	1.4	1
252	EFEMP1 induces Î ³ -secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget, 2014, 5, 363-374.	1.8	41

#	Article	IF	Citations
253	Parents' and Health-Care Providers' Perspectives on Side-Effects of Childhood Cancer Treatment in Indonesia. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3593-3599.	1.2	7
254	Abstract 3775: Identification of PHF6 as a temozolomide resistance factor in glioblastoma using mirConnX. , 2014, , .		0
255	Abstract LB-169: Ratios of immunoproteasome over constitutive proteasome expression are an indicator for sensitivity to bortezomib-containing reinduction chemotherapy in pediatric relapsed ALL and AML., 2014,,.		0
256	Abstract 4764: Transfer of regulatory protein networks via extracellular vesicles as a candidate mechanism of apoptosis-resistance in acute myeloid leukemia. , 2014, , .		0
257	Abstract B34: Increased risk of relapse in non-high-risk children with pediatric B-lineage acute lymphoblastic leukemia can be predicted at diagnosis by microRNA expression. , 2014, , .		0
258	Genetic Aberrations As Putative MRD Targets in Childhood Acute Myeloid Leukaemia. Blood, 2014, 124, 2331-2331.	1.4	0
259	Prediction of Relapse By microRNA Expression in Pediatric B-Lineage Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3793-3793.	1.4	0
260	Microrna-106b~25 Cluster Is Involved in Relapsed MLL-Rearranged Pediatric AML. Blood, 2014, 124, 1038-1038.	1.4	5
261	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	1.4	0
262	Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia. Quality of Life Research, 2013, 22, 677-681.	3.1	16
263	What Constitutes the Best Interest of a Child? Views of Parents, Children, and Physicians in a Pediatric Oncology Setting. American Journal of Bioethics Primary Research, 2013, 4, 1-10.	1.5	10
264	High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia, 2013, 27, 1497-1503.	7.2	54
265	Novel estimating equation of GFR in children without height information performs as well as the Schwartz equation. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 8-8.	0.0	0
266	Glucocorticoid induced adrenal suppression in childhood acute lymphoblastic leukemia. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 46-46.	0.0	0
267	Psychiatric symptoms causing delay in diagnosing childhood cancer: two case reports and literature review. European Child and Adolescent Psychiatry, 2013, 22, 443-450.	4.7	3
268	Adequate endocrine and cardiovascular response to social stress in survivors of childhood acute lymphoblastic leukemia. Psychoneuroendocrinology, 2013, 38, 3145-3149.	2.7	2
269	Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia, 2013, 27, 1786-1789.	7.2	36
270	Healthâ€care providers' perspectives on childhood cancer treatment in Manado, Indonesia. Psycho-Oncology, 2013, 22, 2522-2528.	2.3	14

#	Article	IF	CITATIONS
271	Implementation of a multiâ€institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture. Neuropathology and Applied Neurobiology, 2013, 39, 426-436.	3.2	24
272	High prevalence of complementary and alternative medicine use in the Dutch pediatric oncology population: a multicenter survey. European Journal of Pediatrics, 2013, 172, 31-37.	2.7	45
273	The evolution of comprehensive cancer care in Western Kenya. Journal of Cancer Policy, 2013, 1, e25-e30.	1.4	19
274	Height-Independent Estimation of Glomerular Filtration Rate in Children: An Alternative to the Schwartz Equation. Journal of Pediatrics, 2013, 163, 1722-1727.	1.8	34
275	Hypofractionation vs Conventional Radiation Therapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Matched-Cohort Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 85, 315-320.	0.8	92
276	Absence of <i><scp>SBDS</scp></i> mutations in sporadic paediatric acute myeloid leukaemia. British Journal of Haematology, 2013, 160, 559-561.	2.5	3
277	Proteasome inhibitors in acute leukemia. Expert Review of Anticancer Therapy, 2013, 13, 327-337.	2.4	38
278	Physical exercise training interventions for children and young adults during and after treatment for childhood cancer., 2013,, CD008796.		55
279	Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 479-485.	1.5	89
280	Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy. Haematologica, 2013, 98, 753-759.	3.5	43
281	Validity of self-reported data on pregnancies for childhood cancer survivors: a comparison with data from a nationwide population-based registry. Human Reproduction, 2013, 28, 819-827.	0.9	19
282	WEE1 Kinase Inhibition Enhances the Radiation Response of Diffuse Intrinsic Pontine Gliomas. Molecular Cancer Therapeutics, 2013, 12, 141-150.	4.1	64
283	The volume effect in paediatric oncology: a systematic review. Annals of Oncology, 2013, 24, 1749-1753.	1.2	47
284	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 2013, 31, 599-607.	1.6	197
285	Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. British Journal of Cancer, 2013, 109, 2142-2154.	6.4	46
286	Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. Nature Reviews Clinical Oncology, 2013, 10, 599-604.	27.6	40
287	Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica, 2013, 98, 1896-1904.	3. 5	53
288	Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells. PLoS ONE, 2013, 8, e52143.	2.5	15

#	Article	IF	CITATIONS
289	A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2634-2634.	1.4	3
290	In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma. PLoS ONE, 2013, 8, e61512.	2.5	108
291	Abstract 4628: Alterations in FPGS splicing as a plausible underlying mechanism of MTX resistance in ALL , $2013, , .$		0
292	The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance. Blood, 2013, 122, 3841-3841.	1.4	1
293	Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid. Blood, 2013, 122, 1439-1439.	1.4	0
294	A new era for children with diffuse intrinsic pontine glioma: hope for cure?. Expert Review of Anticancer Therapy, 2012, 12, 1109-1112.	2.4	9
295	Epidemiology of diagnosed childhood cancer in western kenya. Archives of Disease in Childhood, 2012, 97, 508-512.	1.9	31
296	High-quality care for all children with cancer. Annals of Oncology, 2012, 23, 1906-1911.	1.2	18
297	Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy controls. Psychoneuroendocrinology, 2012, 37, 1448-1456.	2.7	24
298	Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. , 2012, , CD008727.		13
299	Impaired bortezomib binding to mutant \hat{l}^2 5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia, 2012, 26, 757-768.	7.2	155
300	Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology. Cancer Treatment Reviews, 2012, 38, 27-35.	7.7	199
301	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, 2012, 120, 3187-3205.	1.4	451
302	A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer, 2012, 12, 363.	2.6	28
303	<scp><i>CBL</i></scp> mutations do not frequently occur in paediatric acute myeloid leukaemia. British Journal of Haematology, 2012, 159, 577-584.	2.5	7
304	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia, 2012, 26, 1313-1320.	7.2	86
305	Blood pressure and body composition in longâ€ŧerm survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2012, 58, 278-282.	1.5	56
306	Effect of corruption on medical care in lowâ€income countries. Pediatric Blood and Cancer, 2012, 58, 325-326.	1.5	15

#	Article	IF	Citations
307	Reporting healthâ€related quality of life scores to physicians during routine followâ€up visits of pediatric oncology patients: Is it effective?. Pediatric Blood and Cancer, 2012, 58, 766-774.	1.5	85
308	Malignant melanoma as second malignant neoplasm in longâ€term childhood cancer survivors: A systematic review. Pediatric Blood and Cancer, 2012, 58, 665-674.	1.5	28
309	The influence of patient reported outcomes on the discussion of psychosocial issues in children with cancer. Pediatric Blood and Cancer, 2012, 59, 161-166.	1.5	29
310	Value of routine bone marrow examination in pediatric acute myeloid leukemia (AML): A study of the Dutch Childhood Oncology Group (DCOG). Pediatric Blood and Cancer, 2012, 59, 1239-1244.	1.5	4
311	Pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 2012, 12, 405-413.	2.4	47
312	Alpe d'HuZes Cancer Rehabilitation (A-CaRe) Research: Four Randomized Controlled Exercise Trials and Economic Evaluations in Cancer Patients and Survivors. International Journal of Behavioral Medicine, 2012, 19, 143-156.	1.7	23
313	18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. Pediatric Radiology, 2012, 42, 418-430.	2.0	60
314	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. Blood, 2012, 120, 888-888.	1.4	3
315	Socio-economic Status Plays Important Roles in Childhood Cancer Treatment Outcome in Indonesia. Asian Pacific Journal of Cancer Prevention, 2012, 13, 6491-6496.	1.2	30
316	Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML. Blood, 2012, 120, 283-283.	1.4	0
317	Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study. Blood, 2012, 120, 884-884.	1.4	0
318	Interferon-Î ³ -Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5. Blood, 2012, 120, 1346-1346.	1.4	2
319	Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse Blood, 2012, 120, 2480-2480.	1.4	0
320	Telomere Length and Telomerase Complex Mutations in Pediatric Acute Myeloid Leukemia. Blood, 2012, 120, 1482-1482.	1.4	0
321	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. Blood, 2012, 120, 538-538.	1.4	6
322	Low Levels of Mir-151-5p and Mir-451 Predict Relapse in Pediatric B-Lineage Acute Lymphoblastic Leukemia Blood, 2012, 120, 2507-2507.	1.4	0
323	Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparaginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy. Blood, 2012, 120, 4227-4227.	1.4	O
324	Cell Sensitivity Assays: The MTT Assay. Methods in Molecular Biology, 2011, 731, 237-245.	0.9	1,474

#	Article	IF	Citations
325	Effects of Growth Hormone Therapy on Bone Mass, Metabolic Balance, and Well-Being in Young Adult Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2011, 33, e231-e238.	0.6	25
326	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Yearbook of Oncology, 2011, 2011, 157-158.	0.1	0
327	High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Blood, 2011, 117, 928-935.	1.4	17
328	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	1.4	58
329	NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood, 2011, 118, 3645-3656.	1.4	250
330	Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica, 2011, 96, 221-230.	3.5	98
331	Monitoring of Tumor Growth and Postâ€Irradiation Recurrence in a Diffuse Intrinsic Pontine Glioma Mouse Model. Brain Pathology, 2011, 21, 441-451.	4.1	53
332	Fatigue in children: reliability and validity of the Dutch PedsQLTM Multidimensional Fatigue Scale. Quality of Life Research, 2011, 20, 1103-1108.	3.1	98
333	WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer, 2011, 11, 156.	2.6	94
334	Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences. BMC Medical Ethics, 2011, 12, 18.	2.4	71
335	Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study. Health and Quality of Life Outcomes, 2011, 9, 25.	2.4	63
336	Pyuria is absent during urinary tract infections in neutropenic patients. Pediatric Blood and Cancer, 2011, 56, 868-870.	1.5	35
337	Cystatin C more accurately detects mildly impaired renal function than creatinine in children receiving treatment for malignancy. Pediatric Blood and Cancer, 2011, 57, 262-267.	1.5	41
338	Costâ€effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: The influence of new medication and diagnostic technology. Pediatric Blood and Cancer, 2011, 57, 1005-1010.	1.5	28
339	Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica, 2011, 96, 1478-1487.	3.5	102
340	Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica, 2011, 96, 384-392.	3.5	74
341	PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget, 2011, 2, 984-996.	1.8	85
342	Using Web-Based and Paper-Based Questionnaires for Collecting Data on Fertility Issues Among Female Childhood Cancer Survivors: Differences in Response Characteristics. Journal of Medical Internet Research, 2011, 13, e76.	4.3	36

#	Article	IF	Citations
343	Treatment of Acute Myeloid Leukemia. Pediatric Oncology, 2011, , 121-160.	0.5	1
344	Abstract 3461: A chemical screen for the identification of novel the rapeutics for pediatric brain tumors. , 2011, , .		0
345	Abstract 3209: Gene expression micro array analysis of diagnosis and matched relapse pediatric AML samples indicates that immune regulatory pathways and epigenetic factors are involved in disease progression., 2011,,.		0
346	Abstract 3462: PARP inhibition sensitizes high grade childhood brain tumors to radiation. , 2011, , .		0
347	Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression. Blood, 2011, 118, 1513-1513.	1.4	1
348	Glucocorticoid-Induced Proliferation and Differentiation of Untreated Pediatric AML Cells. Blood, 2011, 118, 4873-4873.	1.4	0
349	Kaposiform (Spindle Cell) Hemangioendotelioma in a Child With an Unusual Presentation. Journal of Pediatric Hematology/Oncology, 2010, 32, 240-242.	0.6	13
350	A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood, 2010, 116, 2205-2214.	1.4	120
351	High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood, 2010, 116, 2752-2758.	1.4	71
352	Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90. Journal of Clinical Oncology, 2010, 28, 2339-2347.	1.6	265
353	Design of the Quality of Life in Motion (QLIM) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a combined physical exercise and psychosocial training program to improve physical fitness in children with cancer. BMC Cancer, 2010, 10, 624.	2.6	37
354	In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma. Cancer Cell, 2010, 18, 244-257.	16.8	238
355	FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leukemia Research, 2010, 34, 1302-1307.	0.8	7
356	Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatric Blood and Cancer, 2010, 55, 344-348.	1.5	45
357	Pediatric oncologists' attitudes towards involving adolescents in decisionâ€making concerning research participation. Pediatric Blood and Cancer, 2010, 55, 123-128.	1.5	51
358	Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 148, 3-14.	2.5	77
359	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British Journal of Haematology, 2010, 148, 768-776.	2.5	7 5
360	Acute lymphoblastic leukaemia in children – is there a role for MTHFR? – response to Lightfoot <i>etÂal</i> . British Journal of Haematology, 2010, 149, 799-800.	2.5	0

#	Article	IF	Citations
361	Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 2010, 24, 1422-1428.	7.2	124
362	EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia, 2010, 24, 942-949.	7.2	69
363	No Prognostic Impact of the <i>WT1</i> Gene Single Nucleotide Polymorphism rs16754 in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, e523-e526.	1.6	26
364	High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood, 2010, 116, 1747-1754.	1.4	84
365	Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Human Reproduction, 2010, 25, 1520-1527.	0.9	94
366	High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Leukemia, 2010, 24, 2048-2055.	7.2	27
367	Towards individualised treatment in childhood leukaemia. Lancet Oncology, The, 2010, 11, 502-503.	10.7	2
368	Strategies for the analysis of in vitro radiation sensitivity and prediction of interaction with potential radiation modifying agents. International Journal of Radiation Biology, 2010, 86, 458-466.	1.8	6
369	Gemtuzumab Ozogamicin In Refractory Childhood Acute Myeloid Leukemia Blood, 2010, 116, 1075-1075.	1.4	3
370	Central Nervous System (CNS) Involvement In Pediatric Relapsed Acute Myeloid Leukemia: Results and Lessons From Study Relapsed AML 2001/01. Blood, 2010, 116, 184-184.	1.4	2
371	Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study. Blood, 2010, 116, 762-762.	1.4	2
372	High IGSF4 expression In Pediatric Acute Monoblastic Leukemia with t(9;11). Blood, 2010, 116, 3614-3614.	1.4	0
373	Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse. Blood, 2010, 116, 751-751.	1.4	0
374	Clinical and Prognostic Significance of Eosinophilia and $Inv(16)/t(16;16)$ In Pediatric Acute Myelomonocytic Leukemia (AML-M4) Blood, 2010, 116, 1664-1664.	1.4	0
375	Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs). Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 212-220.	1.7	11
376	Paraneoplastic gastroâ€intestinal antiâ€Hu syndrome in neuroblastoma. Pediatric Blood and Cancer, 2009, 52, 396-398.	1.5	22
377	Central nervous system involvement in relapsed acute promyelocytic leukemia. Pediatric Blood and Cancer, 2009, 53, 235-236.	1.5	10
378	Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia, 2009, 23, 262-270.	7.2	143

#	Article	IF	CITATIONS
379	Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood, 2009, 113, 2284-2289.	1.4	130
380	Progression From Free Floating Left Ventricular Vegetation to Immobile Mitral Valve in a Child With Zygomyces Endocarditis. Infectious Diseases in Clinical Practice, 2009, 17, 268-269.	0.3	0
381	Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood, 2009, 113, 5951-5960.	1.4	112
382	Old drug, new lessons. Blood, 2009, 113, 4480-4481.	1.4	0
383	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	383
384	Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection Blood, 2009, 114, 1624-1624.	1.4	1
385	Attenuated AMPA Receptor Expression Allows Glioblastoma Cell Survival in Glutamate-Rich Environment. PLoS ONE, 2009, 4, e5953.	2.5	39
386	Characterization of CEBPA Mutations and Promoter Hypermethylation in Pediatric Acute Myeloid Leukemia Blood, 2009, 114, 1605-1605.	1.4	0
387	High Frequency of Copy Number Variations in Myeloid Leukemia of Down Syndrome Blood, 2009, 114, 3242-3242.	1.4	0
388	VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles Blood, 2009, 114, 997-997.	1.4	1
389	Overexpression of BRE in Pediatric MLL-Rearranged Acute Myeloid Leukemia Associated with t(9;11)(p22;q23) Blood, 2009, 114, 3471-3471.	1.4	0
390	The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene Blood, 2009, 114, 940-940.	1.4	0
391	Psychosexual functioning of childhood cancer survivors. Psycho-Oncology, 2008, 17, 506-511.	2.3	115
392	Circumvention of glucocorticoid resistance in childhood leukemia. Leukemia Research, 2008, 32, 1417-1423.	0.8	5
393	Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia, 2008, 22, 2284-2285.	7.2	25
394	The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study. BMC Pediatrics, 2008, 8, 25.	1.7	17
395	Intravenous administration of the conditionally replicative adenovirus Ad5-Δ24RGD induces regression of osteosarcoma lung metastases. Molecular Cancer, 2008, 7, 9.	19.2	15
396	Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. Health and Quality of Life Outcomes, 2008, 6, 103.	2.4	41

#	Article	IF	CITATIONS
397	Is aggressive local treatment necessary for diffuse liver involvement in patients with progression of stage 4s neuroblastoma to stage 4?. Journal of Pediatric Surgery, 2008, 43, 1630-1635.	1.6	5
398	Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia. Clinical Cancer Research, 2008, 14, 924-930.	7.0	22
399	Immunocytochemical Detection of hENT1 and hCNT1 in Normal Tissues, Lung Cancer Cell Lines, and NSCLC Patient Samples. Nucleosides, Nucleotides and Nucleic Acids, 2008, 27, 787-793.	1.1	8
400	CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncology Reports, 2008, 19, 1517-23.	2.6	16
401	Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood, 2008, 111, 4322-4328.	1.4	118
402	Molecular basis of bortezomib resistance: proteasome subunit \hat{I}^25 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112, 2489-2499.	1.4	406
403	Wilms' Tumor 1 Gene Mutations in Childhood Acute Myeloid Leukemia: A New Prognostic factor with Implications for MRD Detection. Blood, 2008, 112, 144-144.	1.4	3
404	Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia Blood, 2008, 112, 1509-1509.	1.4	1
405	Liposomal Daunorubicin Causes Only Low Cardiotoxicity in Pediatric AML Patients Blood, 2008, 112, 1940-1940.	1.4	1
406	Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cellular Oncology, 2008, 30, 299-306.	1.9	26
407	Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?. Haematologica, 2008, 93, 1418-1420.	3.5	31
408	EVI1 Overexpression in Pediatric Acute Myeloid Leukemia Associated with Unfavorable Subtypes Blood, 2008, 112, 1802-1802.	1.4	0
409	Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment Blood, 2008, 112, 963-963.	1.4	O
410	Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse. Blood, 2008, 112, 2540-2540.	1.4	0
411	Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Molecular Cancer Therapeutics, 2007, 6, 1552-1561.	4.1	30
412	Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor and glucocorticoid induced apoptosis. Annals of the Rheumatic Diseases, 2007, 66, 1289-1295.	0.9	11
413	Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 2007, 92, 1519-1532.	3.5	142
414	Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood, 2007, 109, 4641-4647.	1.4	126

#	Article	IF	CITATIONS
415	Win-WNT pathway in ALL. Blood, 2007, 109, 3135-3136.	1.4	O
416	Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia, 2007, 21, 1584-1587.	7.2	30
417	A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology, 2007, 361, 56-67.	2.4	24
418	Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells Blood, 2007, 110, 3469-3469.	1.4	1
419	Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype Blood, 2007, 110, 366-366.	1.4	1
420	NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation Blood, 2007, 110, 757-757.	1.4	2
421	Methylation of the PTPNS1 Promoter Region in Pediatric Acute Promyelocytic Leukemia Blood, 2007, 110, 4315-4315.	1.4	0
422	Potential for Cure by Chemotherapy Only, without Allogeneic Stem Cell Transplantation, in Pediatric Relapsed Acute Myeloid Leukemia? Blood, 2007, 110, 2865-2865.	1.4	0
423	Differences in Cyto- and Molecular Genetic Abnormalities between Children <2 Years and Older Children with Acute Myeloid Leukemia Blood, 2007, 110, 1830-1830.	1.4	0
424	Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-Analysis of 1929 Cases of Leukemia and Lymphoma Blood, 2007, 110, 3471-3471.	1.4	1
425	Ex Vivo Activity of Bortezomib and Dexamethasone Combinations Against Childhood Acute Leukemia Cells Blood, 2007, 110, 4205-4205.	1.4	0
426	Medulloblastoma: need for targeted treatment. Expert Review of Anticancer Therapy, 2006, 6, 649-652.	2.4	4
427	Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?. Blood, 2006, 107, 4975-4977.	1.4	4
428	Clinical implications of FLT3 mutations in pediatric AML. Blood, 2006, 108, 3654-3661.	1.4	355
429	Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): Single-agent therapeutic window study in relapsed AML. Pediatric Blood and Cancer, 2006, 47, 539-542.	1.5	4
430	Proteasome inhibition as novel treatment strategy in leukaemia. British Journal of Haematology, 2006, 134, 253-262.	2.5	40
431	Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia, 2006, 20, 1217-1220.	7.2	162
432	Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemotherapy and Pharmacology, 2006, 58, 1-12.	2.3	38

#	Article	IF	CITATIONS
433	Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance–associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis and Rheumatism, 2006, 54, 557-568.	6.7	37
434	Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. British Journal of Cancer, 2006, 94, 1837-1844.	6.4	37
435	Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01 Blood, 2006, 108, 2013-2013.	1.4	8
436	Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML Blood, 2006, 108, 838-838.	1.4	1
437	Absence of JAK2 V617F Activating Mutations in Children with Acute Megakaryoblastic Leukemia with and without Down Syndrome Blood, 2006, 108, 4325-4325.	1.4	0
438	FLT3 and KIT Mutated Pediatric Acute Myeloid Leukemia (AML) Samples Are More Sensitive In Vitro to the Tyrosine Kinase Inhibitor SU11657 Blood, 2006, 108, 1359-1359.	1.4	0
439	Hypermethylation of FANCC and FANCL Resulting in a Mitomycine-C (MMC) Sensitive Cellular Phenotype in Sporadic Acute Leukemia Blood, 2006, 108, 2224-2224.	1.4	0
440	In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica, 2006, 91, 17-23.	3.5	21
441	Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood, 2005, 106, 717-720.	1.4	129
442	In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood, 2005, 106, 3532-3537.	1.4	32
443	Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. British Journal of Haematology, 2005, 131, 219-222.	2.5	12
444	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia, 2005, 19, 1536-1542.	7.2	227
445	Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia, 2005, 19, 2063-2071.	7.2	46
446	Pediatric acute myeloid leukemia: international progress and future directions. Leukemia, 2005, 19, 2025-2029.	7.2	161
447	Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. Cancer Chemotherapy and Pharmacology, 2005, 56, 322-327.	2.3	3
448	Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses. Clinical Cancer Research, 2005, 11, 2445-2448.	7.0	15
449	Treatment of childhood acute myeloid leukemia. Expert Review of Anticancer Therapy, 2005, 5, 917-929.	2.4	7
450	The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. British Journal of Cancer, 2005, 93, 1388-1394.	6.4	136

#	Article	IF	Citations
451	The Human Multidrug Resistance Protein MRP5 Transports Folates and Can Mediate Cellular Resistance against Antifolates. Cancer Research, 2005, 65, 4425-4430.	0.9	114
452	Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. European Journal of Cancer, 2005, 41, 1300-1303.	2.8	27
453	Folates and antifolates in the treatment of cancer; role of folic acid supplementation on efficacy of folate and non-folate drugs. Trends in Food Science and Technology, 2005, 16, 289-297.	15.1	10
454	Use of the Differential Staining Cytotoxicity Assay to Predict Chemosensitivity., 2005, 110, 049-058.		0
455	A phase II study of single-agent gemtuzumab ozogamicin in relapsed/refractory pediatric acute myeloid leukemia (AML). Journal of Clinical Oncology, 2005, 23, 8524-8524.	1.6	2
456	Favorable Interactions between Aplidin (Plitidepsin) and Conventional Anticancer Agents in Leukemic Cell Lines and Acute Leukemia Patient Samples Blood, 2005, 106, 4442-4442.	1.4	0
457	Large Interindividual Differences in In Vitro Calicheamicin Sensitivity May Underly Gemtuzumab Ozogamicin Resistance in Acute Myeloid Leukemia (AML) Blood, 2005, 106, 107-107.	1.4	4
458	A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Research, 2005, 65, 291-9.	0.9	79
459	The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. International Journal of Oncology, 2004, 25, 1823.	3.3	1
460	Gemtuzumab Ozogamicin (Mylotarg ^{\hat{A}^{\otimes}}) in Children with Refractory or Relapsed Acute Myeloid Leukemia. Oncology Research and Treatment, 2004, 27, 269-272.	1.2	32
461	Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. British Journal of Haematology, 2004, 127, 264-279.	2.5	28
462	Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia, 2004, 18, 530-537.	7.2	79
463	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochemical Pharmacology, 2004, 67, 1541-1548.	4.4	41
464	Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer, 2004, 100, 773-782.	4.1	42
465	Modulation of Cytarabine Induced Cytotoxicity Using Novel Deoxynucleoside Analogs in the HL60 Cell Line. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1513-1516.	1.1	7
466	Immunocytochemical Detection of Deoxycytidine Kinase in Pediatric Malignancies in Relation to In Vitro Cytarabine Sensitivity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1351-1356.	1.1	6
467	Online Fluorescent Method to Assess BCRP/ABCG2 Activity in Suspension Cells. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1451-1454.	1.1	6
468	In-Vitro Cytotoxicity of Tipifarnib (Zarnestra TM) in Pediatric AML and ALL Samples Is Independent of RAS Mutations Blood, 2004, 104, 1172-1172.	1.4	1

#	Article	IF	Citations
469	Sensitization of Leukemic Cells for Glucocorticoids by Inhibition of NFκB Activity Blood, 2004, 104, 3395-3395.	1.4	1
470	Sensitivity and Cross-Resistance to Deoxynucleoside Analogs in Childhood Acute Leukemia Blood, 2004, 104, 2086-2086.	1.4	0
471	Methotrexate in Relapsed Childhood Acute Myeloid Leukemia: A Single Agent Therapeutic Window Study Blood, 2004, 104, 4509-4509.	1.4	0
472	The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochemical Pharmacology, 2003, 65, 765-771.	4.4	67
473	Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia, 2003, 17, 468-470.	7.2	65
474	In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. Leukemia, 2003, 17, 1338-1343.	7.2	29
475	Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. European Journal of Cancer, 2003, 39, 691-697.	2.8	43
476	Patient Stratification Based on Prednisolone-Vincristine-Asparaginase Resistance Profiles in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2003, 21, 3262-3268.	1.6	164
477	Targeted monoclonal antibody-based treatment of hematological malignancies. Expert Review of Anticancer Therapy, 2003, 3, 253-255.	2.4	1
478	Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. British Journal of Cancer, 2003, 88, 775-781.	6.4	31
479	Past, current and future protocols for combined modality therapy in childhood medulloblastoma. Expert Review of Anticancer Therapy, 2003, 3, 79-90.	2.4	5
480	Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 2003, 101, 3868-3871.	1.4	94
481	FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 2003, 102, 2387-2394.	1.4	214
482	Clinical Significance of Cellular Drug Resistance in Childhood Leukemia. Recent Results in Cancer Research, 2003, 161, 196-220.	1.8	13
483	Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia. Oncology Reports, 2003, 10, 2027-31.	2.6	3
484	Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood, 2002, 100, 3352-3360.	1.4	61
485	Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood, 2002, 99, 245-251.	1.4	153
486	Congenital leukaemia: the Dutch experience and review of the literature. British Journal of Haematology, 2002, 117, 513-524.	2.5	136

#	Article	IF	Citations
487	A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. European Journal of Cancer, 2001, 37, 492-498.	2.8	18
488	Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia, 2001, 15, 1066-1071.	7.2	43
489	Pediatric leukemia in the new millennium. Expert Review of Anticancer Therapy, 2001, 1, 1-2.	2.4	3
490	Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. British Journal of Haematology, 2000, 109, 427-429.	2.5	40
491	Classification OfEx VivoMethotrexate Resistance In Acute Lymphoblastic and Myeloid Leukaemia. British Journal of Haematology, 2000, 110, 791-800.	2.5	41
492	Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia. Blood, 1999, 93, 1677-1683.	1.4	120
493	Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. Blood, 1999, 94, 3121-3128.	1.4	213
494	Different expression of glutathione S-transferase \hat{l}_{\pm} , \hat{l}_{+}^{\prime} and \ddot{l}_{\pm} in childhood acute lymphoblastic and myeloid leukaemia. British Journal of Haematology, 1999, 104, 321-327.	2.5	28
495	Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia, 1999, 13, 1574-1580.	7.2	69
496	Effects of interleukin 3, interleukin 7, and B-cell growth factor on proliferation and drug resistance in vitro in childhood acute lymphoblastic leukemia. Annals of Hematology, 1999, 78, 163-171.	1.8	10
497	BCL-2 Expression in Childhood Leukemia Versus Spontaneous Apoptosis, Drug Induced Apoptosis, and in vitro Drug Resistance. Advances in Experimental Medicine and Biology, 1999, 457, 325-333.	1.6	20
498	Resistance Testing and Mechanisms of Resistance in Childhood Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 391-395.	1.6	2
499	Lack of Cross-Resistance Between Prednisolone and Methotrexate in Childhood Acute Lymphoblastic Leukemia?. Advances in Experimental Medicine and Biology, 1999, 457, 551-555.	1.6	2
500	Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay. Blood, 1999, 93, 1067-1074.	1.4	13
501	Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia. Blood, 1999, 93, 1677-1683.	1.4	6
502	Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. Blood, 1999, 94, 3121-3128.	1.4	3
503	Computer Assisted Orthopaedic Surgery With Image Based Individual Templates. Clinical Orthopaedics and Related Research, 1998, 354, 28-38.	1.5	223
504	Prednisolone Resistance in Childhood Acute Lymphoblastic Leukemia: Vitro-Vivo Correlations and Cross-Resistance to Other Drugs. Blood, 1998, 92, 259-266.	1.4	151

#	Article	IF	CITATIONS
505	Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia. Blood, 1998, 91, 2092-2098.	1.4	92
506	Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 1997, 25, 11-26.	4.4	51
507	In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. Blood, 1997, 90, 2723-2729.	1.4	12
508	Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-l-aspartate in human leukemic blast cells and cell lines. Leukemia Research, 1996, 20, 127-134.	0.8	22
509	Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia., 1996, 27, 114-121.		87
510	Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leukemia Research, 1995, 19, 175-181.	0.8	27
511	Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood, 1995, 85, 751-756.	1.4	133
512	In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood, 1995, 86, 3861-3868.	1.4	195
513	Clinical and Cell Biological Features Related to Cellular Drug Resistance of Childhood Acute Lymphoblastic Leukemia Cells. Leukemia and Lymphoma, 1995, 19, 407-416.	1.3	35
514	Glucocorticoid Resistance in Childhood Leukemia. Leukemia and Lymphoma, 1994, 13, 187-201.	1.3	84
515	Cellular drug resistance in childhood leukemia. Annals of Hematology, 1994, 69, S31-S34.	1.8	4
516	Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art. Medical and Pediatric Oncology, 1994, 22, 299-308.	1.0	31
517	Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. British Journal of Cancer, 1994, 70, 1047-1052.	6.4	114
518	In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. British Journal of Cancer, 1991, 64, 469-474.	6.4	96
519	Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood cancer and cancer in the reproductive age. The Cochrane Library, 0, , .	2.8	0